随着预防性疫苗和肿瘤治疗两大mRNA主赛道日益成熟，全球mRNA产业正急需拓展新的技术方向和商业空间。相比疫苗与肿瘤治疗通常面临的突变抗原和免疫逃逸问题，自身免疫病中相对稳定的自身抗原靶点，使其天然适配mRNA诱导免疫耐受的机制。

脊髓损伤（SCI）严重损害中枢神经系统，导致严重神经功能缺损和长期残疾。研究人员开展了巨噬细胞靶向 Mms6 mRNA - 脂质纳米颗粒（LNPs）促进 SCI 小鼠运动功能恢复的研究。结果显示，该纳米颗粒能增强巨噬细胞抗铁死亡能力，促进脊髓形态修复和功能恢复，为 SCI 治疗提供新策略。

近日，中国科学技术大学生物医学工程学院王育才教授课题组通过体内筛选优化得到的低免疫原性LNPs，成功在体内直接编程生成耐受性抗原呈递细胞（tol-APCs），治疗自身免疫性疾病（AIDs）。相关研究成果以“Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 ...

A new study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable ...

A breakthrough in safely delivering therapeutic DNA to cells using lipid nanoparticles could transform treatment for millions ...

Researchers have identified cellular factors that regulate the delivery and stability of mRNA to expand the potential of mRNA ...

Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 ...

Sunshine Biopharma (SBFM) has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid ...

Researchers develop innovative phospholipids that improve the functional delivery of mRNA via lipid nanoparticles, paving the ...

Following encapsulation in two specifically designed Lipid Nanoparticles, the resulting K1.1c-mRNA-LNP and K1.1d-mRNA-LNP were efficiently delivered to orthotopic engrafted HCC tumors in mice in a ...

A study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable of ...